BioCryst ( (BCRX) ) has issued an announcement.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
BioCryst Pharmaceuticals reported a strong Q3 2024 with ORLADEYO net revenue of $116.3 million, growing 35.7% year-over-year, and adjusted full-year revenue guidance to $430-$435 million. The company introduced additional revenue guidance of $443-$448 million including RAPIVAB and achieved a GAAP operating profit of $7.7 million. Advancements in their pipeline include BCX17725 for Netherton syndrome and avoralstat for DME, showcasing significant progress and a robust outlook for sustainable profitability.
For detailed information about BCRX stock, go to TipRanks’ Stock Analysis page.
